基于纳米载体的药物递送系统在类风湿性关节炎治疗中的研究进展

Recent advances in nanocarrier-based drug delivery systems in treatment of rheumatoid arthritis

类风湿性关节炎是一种广泛存在的自身免疫性炎症性疾病,严重影响患者的生活质量。目前用于治疗RA的常规剂型存在诸多局限性,例如非特异性、疗效不佳、用药剂量大、给药频繁以及全身性副作用。目前,纳米技术已经能够解决传统治疗的局限性并简化疾病的复杂性,因此基于纳米技术的药物递送系统正逐渐成为一种用于RA诊断和治疗的新策略,其可使负载的抗炎药物通过主动和被动靶向至发炎区域,实现对关节的特异性、克服剂量和给药频率的增加以及与之相关的不良反应。该文旨在对近年来基于纳米载体的药物递送系统在RA领域中的最新研究进行归纳总结,并阐述如何使用纳米系统将治疗药物输送到发炎关节以控制RA进展。通过探讨目前纳米药物递送系统可能存在的问题以及亟待解决的挑战,为未来深入研究基于纳米技术的共递系统提供理论支持。

Rheumatoid arthritis(RA)is a widely prevalent autoimmune inflammatory disease that severely affects patients'quality of life.Currently,conventional formulations against RA have several limitations,such as nonspecificity,poor efficacy,large drug dosa-ges,frequent administration,and systemic side effects.Nanotechnology-based drug delivery systems have emerged as a promising stra-tegy for the diagnosis and treatment of RA since nanotechnology can overcome the limitations of traditional treatments and simplify the complexity of the disease.These systems enable targeted delivery of anti-inflammatory drugs to the inflamed areas through active and passive targeting,achieving specificity to the joints,overcoming the need for increased dosage and administration frequency,and re-ducing associated adverse reactions.This article aimed to review nanocarrier-based drug delivery systems in the field of RA and eluci-date how nanosystems can be utilized to deliver therapeutic drugs to inflamed joints for controlling RA progression.By discussing the current issues and challenges faced by nanodrug delivery systems and highlighting the urgent need for solutions,this article offers theoretical support for further research on nanotechnology-based co-delivery systems in the future.